| RYAPX | RYVNX | RYAPX / RYVNX | |
| Total Expense Ratio | 1.68 | 1.79 | 94% |
| Annual Report Gross Expense Ratio | 1.79 | 1.89 | 95% |
| Fund Existence | 22 years | 26 years | - |
| Gain YTD | -9.917 | -22.971 | 43% |
| Front Load | 5% | N/A | - |
| Min. Initial Investment | 2500 | 2500 | 100% |
| Min. Initial Investment IRA | 1000 | 1000 | 100% |
| Net Assets | 76.9M | 13.1M | 587% |
| Annual Yield % from dividends | 2.61 | 13.79 | 19% |
| Returns for 1 year | -15.82 | -34.33 | 46% |
| Returns for 3 years | -44.60 | -73.49 | 61% |
| Returns for 5 years | -51.95 | -83.05 | 63% |
| Returns for 10 years | -88.11 | -99.20 | 89% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BST | 46.26 | 0.59 | +1.29% |
| BlackRock Science and Technology Trust | |||
| JULB | 27.67 | 0.15 | +0.54% |
| Aptus July Buffer ETF | |||
| DYLD | 22.26 | N/A | -0.02% |
| LeaderShares® Dynamic Yield ETF | |||
| FDEV | 37.15 | -0.31 | -0.83% |
| Fidelity International Multifactor ETF | |||
| THNR | 25.40 | -0.47 | -1.81% |
| Amplify Weight Loss Drug & Treatment ETF | |||